<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449058</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2109</org_study_id>
    <secondary_id>2011-002578-21</secondary_id>
    <nct_id>NCT01449058</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration (TGA)</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Switzerland: Swissmedic</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum
      tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally
      administered combination of BYL719 and MEK162. This combination will be explored in adult
      patients with advanced CRC, esophageal cancer, pancreatic cancer, NSCLC, ovarian cancer, or
      other advanced solid tumors and in adult patients with AML or high risk and very high risk
      MDS, with documented RAS or BRAF mutations. Dose escalation will be guided by a Bayesian
      logistic regression model with overdose control. At MTD or RDE, four expansion arms will be
      opened in order to further assess the safety and preliminary activity of the combination of
      BYL719 and MEK162 in specific patient populations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLT)</measure>
    <time_frame>during the first cycle (28 days) of treatment with BYL719 and MEK162</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicity will be assessed using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0 unless otherwise specified. A DLT is defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the study medication, occurs ≤ 28 days following the first dose of BYL719 and MEK162 (Cycle 1), and meets any of the protocol-specified DLT criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events</measure>
    <time_frame>Assessed from Cycle 1 Day 1 until treatment discontinuation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All AEs and SAEs will be collected in accordance with the protocol and assessed for relatedness to study drug combination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Assessed every 8 weeks until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate (ORR) is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Assessed every 8 weeks until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to progression (TTP) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to underlying cancer. If a patient has not had an event, time to progression is censored at the date of last adequate tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Assessed every 8 weeks until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time versus plasma concentration profiles of BYL719 and MEK162</measure>
    <time_frame>Assessed during the first cycle of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood concentrations of MEK162 and its metabolite (AR00426032) and BYL719 will be assessed during the first cycle of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of baseline mutation or amplification status (PIK3CA, KRAS, NRAS and BRAF) and clinical anti-tumor activity outcome</measure>
    <time_frame>Assessed at Baseline (pre-treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Collect baseline genetic mutation/alteration status to investigate the potential relationship to anti-tumor activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Assessed every 4 weeks for 3 months and every 3 months for 6 months followed by every 6 months thereafter until disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>The clinical benefit rate is defined as the proportion of patients with complete remission, complete remission with incomplete blood count recovery, partial remission, minor response or stable disease for &gt; 15 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS</condition>
  <arm_group>
    <arm_group_label>BYL719 + MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719 plus MEK162</intervention_name>
    <description>BYL719 plus MEK162 administered in this dose escalation study until MTD/RDE is achieved, followed by a dose expansion phase.</description>
    <arm_group_label>BYL719 + MEK162</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed, advanced solid tumors, AML or high risk and
             very high risk MDS

          -  Measurable disease as determined by RECIST 1.1

        Exclusion Criteria:

          -  Primary CNS tumor or CNS tumor involvement

          -  Diabetes mellitus

          -  Unacceptable ocular/retinal conditions

          -  Clinically significant cardiac disease or impaired cardiac function
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Array BioPharma</last_name>
    <role>Study Director</role>
    <affiliation>303-381-6604</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Array BioPharma Clinical Trial Call Center</last_name>
    <phone>303-381-6604</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego - Moores Cancer Center Dept Onc</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute H. Lee Moffitt SC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sumin Hassani</last_name>
      <phone>813-745-1807</phone>
      <email>simin.hassani@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Magliocco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Hoyer</last_name>
      <phone>312-695-1341</phone>
      <email>amy.hoyer@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zachary T Kisley</last_name>
      <phone>+1 312-695-1476</phone>
      <email>zachary.kisley@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Young L. Chae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CCPO</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dejan Juric</last_name>
      <phone>617-724-4000</phone>
      <email>CQUADRINO@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Dejan Juric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center SC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markenya Almanzar</last_name>
      <phone>718-405-8545</phone>
      <email>lalmanza@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Kira Gritsman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Onc. Dept</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raajit Rampal</last_name>
      <phone>212-639-2194</phone>
      <email>rampalr@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Raajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Dept. of Onc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute Huntsman (3)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 21, 2016</lastchanged_date>
  <firstreceived_date>October 6, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumor,</keyword>
  <keyword>AML</keyword>
  <keyword>high risk and very high risk MDS</keyword>
  <keyword>dose escalation,</keyword>
  <keyword>RAS/BRAF mutation,</keyword>
  <keyword>PI3K inhibitor,</keyword>
  <keyword>MEK inhibitor,</keyword>
  <keyword>BYL719,</keyword>
  <keyword>MEK162</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
